Non-surgical treatment of infant’s subglottic hemangiomas

Abstract

The objective of the study: to analyse the experience of non-surgical treatment of infant’s subglottic hemangiomas using non-selective β­ blocker propranolol. The results: At the period of 2011 through 2016 seven children, diagnosed with congenital disorder – the infant’s subglottic hemangioma – were observed in Otorhinolaryngology Clinic of Saint Petersburg State Pediatric Medical University. All of them were treated with glucocorticosteroids as a starting therapy. Propranolol therapy started immediately after diagnostics and consultation of a cardiologist and vascular surgeon. Persistent hemangioma regress and the absence of larynx stenosis symptoms were registered in all the patients. The observation period constituted 6 months through 4 years. Propranolol therapy duration was determined individually: 1 year through 2 years. No side effects from propranolol administration have been observed. Conclusion: We consider that Propranolol can be recommended as a basic therapy of infant`s subglottic hemangiomas together with a short course of glucocorticosteroids as a starting therapy.